
FDA Grants Orphan Drug Designation to Taladegib, Potential Idiopathic Pulmonary Fibrosis Treatment
The FDA has granted orphan drug designation to Endeavor Biosciences’ Taladegib (ENV-101) for the treatment of idiopathic pulmonary fibrosis (IPF).1 “Receiving Orphan Drug Designation for taladegib in both the United States and European Union underscores …